Oncology nurses have an important role to play — and a legal responsibility — to recognize and ameliorate inequities that could affect patient compliance and access to cancer care for patients with disabilities.
Too few patients receive biomarker testing to inform diagnosis, prognosis, and treatment decision making, and racial, geographic and other disparities put some patients at particular disadvantage.
Adding ipilimumab to treatment with nivolumab does not provide a clinically meaningful benefit in patients with certain cancers, a meta-analysis suggests.
